Neurex Corlopam Phase IV studies will examine fenoldopam/beta blocker interaction.
NEUREX CORLOPAM CONCOMITANT USE STUDY WITH BETA BLOCKERS will be conducted by the company in Phase IV. Corlopam (fenoldopam mesylate) 10 mg/mL injection was approved Sept. 23 for management of severe hypertension in hospital settings. FDA has suggested that Neurex "contact the Division of Cardio-Renal Drug Products to schedule a meeting to discuss the objectives and design of the trial."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth